...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: ZEN-3694 Single Agent Trial Status
6
Oct 24, 2017 11:18AM
1
Oct 25, 2017 09:02AM
2
Oct 26, 2017 10:24AM
5
Oct 26, 2017 12:13PM

Nov 02, 2017 03:38PM

Nov 02, 2017 04:29PM

Nov 03, 2017 10:49AM

Nov 03, 2017 10:58AM

Nov 03, 2017 12:07PM
2
Nov 03, 2017 03:45PM
2
Nov 03, 2017 04:23PM
5
Nov 18, 2017 07:45PM

,,,hummm,,, I am just suspicious that if a deal or deals come along which might indicate good value but yet we will still sit in limbo with no way to transact these shares. What value the open market gives us is just a guess when we are not listed. Something tells me when we were spun off from RVX that the market share price of RVX dropped by a dollar,,,but that was so long ago its getting fuzzy. And the team seems to think we are worth much more based on their theorized market cap. It would be nice to actually have concrete valuation on us!!!!

Evolution seems to happen faster than futhering the science in these biotech companies,,,,,,so it is very frustrating that we own a % of an asset which we have really no way of divesting off...especially if timing of a disposition is critical to a shareholder!!,,,so with RVX at $2 and if ZEN was even at $1.50,,,I would feel like we are gaining,,slowly but none the less gaining in this investment.......jmo

Share
New Message
Please login to post a reply